A Phase 3 interventional study of FST-201 (dexamethasone 0.1%) Otic Suspension and ciprofloxacin 0.3%, dexamethasone 0.1% in Acute Otitis Externa, sponsored by Shire. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-27.
Sponsored by Shire · Phase 3, Interventional, and Treatment
The objective of this study is to evaluate the efficacy of FST-201 compared to Ciprodex in the treatment of acute otitis externa. This trial is designed to enable filing of a New Drug Application in support of FST-201 for the indication of acute otitis externa.
Exclusion Criteria:
All subjects must not:
Drug: FST-201 (dexamethasone 0.1%) Otic Suspension
Drug: ciprofloxacin 0.3%, dexamethasone 0.1%
Instill four drops two times a day
Instill four drops two times a day
Also known as: Ciprodex
Overall clinical cure as defined by absence of the signs and symptoms of AOE including ear inflammation, edema, tenderness and otic discharge.
Time frame: 1 year
Microbiological resolution defined as elimination of pre-treatment pathogenic bacteria.
Time frame: 1 year
This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shire